Assessing the Impact of Pandemic-Related Social Distancing Mandates on Bloodstream Infection Rates in Children With

Rachel Offenbacher1,2, Helen S Tian3, Sara Kaswan2

  • 1Department of Pediatrics, Albert Einstein College of Medicine and Division of Pediatric Hematology, Oncology and Cellular Therapy.

Insights

The COVID-19 pandemic

Area of Science:

  • Pediatric Oncology
  • Infectious Diseases
  • Epidemiology

Background:

  • Children with severe neutropenia face high infection risks, necessitating avoidance of infectious disease risk factors (IDRFs).
  • The COVID-19 pandemic's social distancing measures reduced exposure to environmental IDRFs, offering a unique study opportunity.
  • Understanding IDRF exposure impact on bacteremia in neutropenic children is crucial for clinical guidance.

Purpose of the Study:

  • To compare the incidence of fever and bloodstream infections in children with chemotherapy-induced neutropenia before and during COVID-19 pandemic lockdowns.
  • To assess the influence of reduced environmental infectious disease risk factor exposure on infection rates.

Main Methods:

  • Retrospective chart review of pediatric patients with neutropenia.
  • Comparison of infection rates (fever, bacteremia) during two 1-year periods: pre-pandemic (March 2019-2020) and pandemic (March 2020-2021).

Main Results:

  • No statistically significant difference in febrile neutropenia incidence (IRR=0.89, P=0.38) was observed.
  • No statistically significant difference in febrile neutropenic bloodstream infection incidence (IRR=1.01, P=0.99) was found.
  • Infection rates remained similar despite differing levels of environmental IDRF exposure.

Conclusions:

  • Reduced exposure to environmental infectious disease risk factors during the COVID-19 pandemic did not significantly alter infection rates in neutropenic children.
  • Further multicenter research is required to fully elucidate the risks associated with environmental exposures for neutropenic children.
  • Findings may inform future clinical guidelines for managing infection risk in pediatric oncology patients.